Advanced Dedifferentiated Liposarcoma: Systemic Therapy

Authored by Michael Wagner, published on 2026-06-03 19:44:02.0

  1. GOALS OF THERAPY
    Prolong survival Delay progression Maintain function/quality of life Manage symptoms
  2. CLINICAL TRIALS: CONSIDER AT EVERY LINE
    Strongly encourage enrollment in clinical trials, including studies of: CDK4 inhibitors (combinations) MDM2 inhibitors Immunotherapy combinations Novel targeted agents Cellular therapies Refer to clinicaltrials.gov
  3. FUTURE DIRECTIONS
    Biomarker Development: CDK4 amplification, RB1 status, cell cycle signatures Rational Combinations: CDK4 inhibitor + MDM2 inhibitor; CDK4 inhibitor + immune therapy; CDK4 inhibitor + other targeted agents Overcoming Resistance: Identify resistance mechanisms and optimal sequencing/combination strategies Patient-Centered Care: Optimize QOL, symptom control, shared decision-making through all lines
  4. Diagnostic workup (at sarcoma center)
    Suspected WDLPS/DDLPS: Expert pathology review with testing for MDM2 amplification MRI (extremity) or CT abdomen/pelvis (retroperitoneal) CT chest staging Core needle biopsy if needed Multidisciplinary tumor board review Discussion of surgery, radiation, systemic therapy, and clinical trials
    • DIAGNOSIS: ADVANCED DEDIFFERENTIATED LIPOSARCOMA (DDLPS)
      Unresectable locally advanced and/or metastatic disease Confirm DDLPS (MDM2 amplification ±) Histology review as needed
      • INITIAL ASSESSMENT
        Performance status (ECOG) Disease tempo / tumor burden Symptoms and organ function Prior systemic therapy Patient goals and preferences
        • INDOLENT DISEASE
          Low tumor burden/slow growth Minimally symptomatic ECOG 0–1
          • FIRST-LINE OPTIONS: ABEMACICLIB (CDK4 inhibitor) or Chemotherapy
            Consider either abemaciclib or chemotherapy based on patient characteristics, goals, etc. Abemaciclib is based on SARCO41 (LBA2) ASCO 2026 Rationale: High CDK4 pathway activation in DDLPS; SARCO41 demonstrates clinically meaningful activity and manageable safety Monitor: CBC (neutropenia), diarrhea, LFTs Dose modify as needed Reassess every 8–12 weeks Chemotherapy
            • REASSESS RESPONSE / TOLERABILITY
              Imaging every 8–12 weeks
              • DISEASE CONTROL (CR/PR/SD) AND TOLERABLE
                • CONTINUE CURRENT THERAPY
                  Continue until progression or unacceptable toxicity
              • PROGRESSION OR UNACCEPTABLE TOXICITY
                • SEQUENCING OPTIONS
                  Choose based on: Prior therapy Disease tempo Performance status Patient preference
                  • After Abemaciclib
                    Anthracycline-based chemotherapy (if not previously used) Eribulin Trabectedin Gemcitabine + Docetaxel Gemcitabine + Dacarbazine
                    • Later Lines
                      Gemcitabine + Docetaxel Gemcitabine + Dacarbazine Ifosfamide (selected)
                      • Best Supportive Care
                        Where appropriate; focus on symptoms, function, and goals.
                  • After Anthracycline
                    Abemaciclib (if not used) Eribulin Trabectedin Gemcitabine + Docetaxel Gemcitabine + Dacarbazine
                    • Later Lines
                      Gemcitabine + Docetaxel Gemcitabine + Dacarbazine Ifosfamide (selected)
                      • Best Supportive Care
                        Where appropriate; focus on symptoms, function, and goals.
                  • Best Supportive Care
                    Where appropriate; focus on symptoms, function, and goals.
              • MIXED RESPONSE / LOCALIZED PROGRESSION WITH OVERALL CONTROL
                • CONSIDER LOCAL THERAPY
                  Surgery, radiation, ablation + Continue systemic therapy if benefiting
        • AGGRESSIVE DISEASE
          High tumor burden / rapid progression Symptomatic / organ compromise
          • FIRST-LINE OPTIONS: ANTHRACYCLINE-BASED CHEMOTHERAPY
            ANTHRACYCLINE-BASED CHEMOTHERAPY, e.g. Doxorubicin. Consider upfront in fit patients with high-risk disease requiring rapid tumor control.
            • REASSESS RESPONSE / TOLERABILITY
              Imaging every 8–12 weeks
              • DISEASE CONTROL (CR/PR/SD) AND TOLERABLE
                • CONTINUE CURRENT THERAPY
                  Continue until progression or unacceptable toxicity
              • PROGRESSION OR UNACCEPTABLE TOXICITY
                • SEQUENCING OPTIONS
                  Choose based on: Prior therapy Disease tempo Performance status Patient preference
                  • After Abemaciclib
                    Anthracycline-based chemotherapy (if not previously used) Eribulin Trabectedin Gemcitabine + Docetaxel Gemcitabine + Dacarbazine
                    • Later Lines
                      Gemcitabine + Docetaxel Gemcitabine + Dacarbazine Ifosfamide (selected)
                      • Best Supportive Care
                        Where appropriate; focus on symptoms, function, and goals.
                  • After Anthracycline
                    Abemaciclib (if not used) Eribulin Trabectedin Gemcitabine + Docetaxel Gemcitabine + Dacarbazine
                    • Later Lines
                      Gemcitabine + Docetaxel Gemcitabine + Dacarbazine Ifosfamide (selected)
                      • Best Supportive Care
                        Where appropriate; focus on symptoms, function, and goals.
                  • Best Supportive Care
                    Where appropriate; focus on symptoms, function, and goals.
              • MIXED RESPONSE / LOCALIZED PROGRESSION WITH OVERALL CONTROL
                • CONSIDER LOCAL THERAPY
                  Surgery, radiation, ablation + Continue systemic therapy if benefiting
tosprivacySARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma